A Supply Disruption Alert has been issued by Department of Health & Social Care (DHSC) on 25th June 2020 for Phenelzine Sulphate 15mg tablets (Nardil®).
Following long-term issues with the supply of Phenelzine Sulphate 15mg tablets (Nardil®) since August 2019, Kyowa Kirin have confirmed that this is likely to be an ongoing problem until the end of 2021 at the earliest.
Imported tablets had previously been used to support the supply to UK patients, however these supplies have become stretched. Supplies of unlicensed phenelzine 15mg capsule specials have become available.
The SDA lists the following actions to be taken by healthcare professionals:
- no new patients should be initiated on phenelzine;
- all patients currently prescribed phenelzine should be reviewed by specialist mental health services to determine if this is still the most appropriate treatment and whether gradual withdrawal in order to stop and switch to an alternative agent is a potential management option; and
- where unlicensed imports of phenelzine 15mg tablets are unavailable, clinicians should consider prescribing specials of phenelzine 15mg capsules to avoid abrupt withdrawal.